Rag2-KO/hVEGFR2
Nomenclature
C57BL/6JSmo-Rag2em1Kdrtm2(hKDR)Smoc
Cat. NO.
NM-HU-200280
Strain State
Embryo Cryopreservation
Model Description
Validation Data
Fig1. In vivo anti-tumor response of Cyramza and Avastin in the treatment of gastric cancer PDX model(GA2419)in the immunodeficient Rag2-KO/hKDR mice. (Completed in collaboration with CrownBio)
(A)Breeding scheme for development of Rag2-KO/hKDR mice; (B) Tumor growth curves upon treatment of Cyramza and Avastin; (C) Body weight change upon treatment.
Fig2. In vivo anti-tumor response of Cyramza in thetreatment of liver cancer PDX model(LI0612)in the im-munodeficient Rag2-KO/hKDR mice. (Completed in collaboration with CrownBio)
(A)Tumor blood vesselstaining via anti-human VEGFR2 IHC; (B) Tumor growth curves upon Cyramza treatment; (C)Body weight change upon treatment.
You may also like
Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute
On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.
Learn moreCustomizing Mouse Models: Delivering in 100 Days to Speed Up Your Research!
At GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.
Learn moreMilestones
Our vision is to provide researchers all over the world with comprehensive, convenient and professional animal model services to facilitate a simplified and highly-efficient approach towards uncovering the mysteries of life.
Learn more
